A recent paper by Gen Li et al. (1) identifies clonidine-displacing substance (CDS) as agmatine. Although agmatine may well displace clonidine from clonidine sites, it differs markedly from the chemical and physiological properties of CDS, which was isolated and characterized in our laboratory in 1984 (2) . We would like to clear up any potential confusion about the identities of these two compounds.
Clonidine-displacing substance was initially isolated from bovine brain (2) and then from serum (3) and cerebrospinal fluid (4) , and has been characterized for its pharmacological properties (5) (6) (7) . The isolation procedure of CDS from brain included aqueous and methanolic extractions followed by four successive reversed-phase and sizing high-performance liquid chromatography (HPLC) steps. The final purification step on a C8 reversed-phase column eluted with water to acetonitrile gradient containing 0.1% trifluoroacetic acid (TFA) (Fig. 1) shows that CDS is retained on the HPLC reversed-phase column, unlike agmatine, which flows through with the void volume.
Characterization of the physical and molecular properties shows that CDS is not a peptide and is heat-and acid (pH 2.0)-resistant, ninhydrin-and fluorescaminenegative, hydrophobic by its retention time on a C8 reversed-phase column (Fig. 1) , and partitions into the aqueous phase in mixtures of chloroform:water and dioxane:water. Agmatine is ninhydrin-positive by virtue of its primary amino group and is not retained on a reversed-phase column.
The estimated molecular mass of CDS determined by size exclusion chromatography was 500 daltons (2) , and its precise mass was determined by plasma desorption mass spectrometry (PDMS) (8) . A mass spectrum showed that the molecular ion was mlz 587.8 ± 2, and the appearance of its dimer at m/z 1174 confirmed the monomer's molecular mass (Fig. 2) . Agmatine In her comment, Atlas suggests that agmatine and CDS differ in chemical and biological properties. While this well may be the case, she has yet to establish the structure of CDS, which weakens her arguments with respect to chemical differences and raises questions about whether all or some of the biological actions of partially purified CDS can be attributed to the same molecule responsible for ligand displacement.
Central to Atlas' argument for structural differences is data, summarized in her table 1 and published papers (1, 5) and agmatine is not meaningful.
Sixth, it is conceivable that agmatine itself may exist in several forms as a result of its ability to carry charge as bound or aggregated forms modifying apparent size, ninhydrin-positivity, and other molecular properties.
Finally, the possibility of multiple molecules being present in what may appear to be a clean HPLC peak is shown by our data.
The absence of structure also raises questions relating to the biological activities of CDS. Are the actions of partially purified CDS on blood pressure (2, 6), platelet aggregation (7), vasoconstriction (8) , gastric contraction (9), or catecholamine release (10), as studied by Atlas or ourselves, attributable to a single molecule? If so, is it the same one binding to a2-adrenergic and imidazoline receptors? Is it agmatine? Complicating the problem is the fact that, as indicated in Atlas' papers, the CDS used for bioassays was not subjected to the same detailed purification steps as used for chemical characterization. Variations in preparations may underlie the fact that microinjection of partially purified CDS into comparable regions of brainstem yield opposite effects on blood pressure when performed by different groups of investigators (1, 6) .
Whether the biological actions attributed to partially purified CDS are shared by agmatine is still not clear for the reasons given. For example, the comment by Atlas cites unpublished data that agmatine does not replicate the actions of CDS in releasing insulin from pancreatic islet cells. Others have published that agmatine stimulates (dependent on dose) insulin release and facilitates accumulation of 45Ca2+ into pancreatic islets (11) . In our hands agmatine, like CDS (10) , stimulates (dependent on dose) release of catecholamines from adrenal chromaffin cells. However, unlike CDS, agmatine injected into the aforementioned brainstem sites did not affect blood pressure.
Without a defined molecule, biological characterization of CDS is imprecise.
It is possible that a substance or substances other than agmatine may exist in
